Oral Drug Delivery of Live Biotherapeutics for First In Human Studies
|
|
- Ruby Dennis
- 6 years ago
- Views:
Transcription
1 Oral Drug Delivery of Live Biotherapeutics for First In Human Studies Presented by Mike Frodsham Pharmaceutical Development Manager
2 About Quay Pharmaceuticals
3 About Quay Pharmaceuticals Contract development and clinical manufacturing organisation based in UK with a global customer base
4 About Quay Pharmaceuticals Contract development and clinical manufacturing organisation based in UK with a global customer base Just opened a new lab in Israel to translate some of the innovation occurring there in to our development programs to support our customers
5 About Quay Pharmaceuticals Contract development and clinical manufacturing organisation based in UK with a global customer base Just opened a new lab in Israel to translate some of the innovation occurring there back in to our development programs Formulate for small and large molecules, live bacteria and phages - for systemic and localised delivery
6 About Quay Pharmaceuticals Contract development and clinical manufacturing organisation based in UK with a global customer base Just opened a new lab in Israel to translate some of the innovation occurring there back in to our development programs Formulate for small and large molecules, live bacteria and phages - for systemic and localised delivery Known for formulation strength in targeted delivery and application of novel engineering solutions for GMP manufacture, to support our customers into clinic quickly and effectively.
7 About Quay Pharmaceuticals Contract development and clinical manufacturing organisation based in UK with a global customer base Just opened a new lab in Israel to translate some of the innovation occurring there back in to our development programs Formulate for small and large molecules, live bacteria and phages - for systemic and localised delivery Known for formulation strength in targeted delivery and application of novel GMP engineering solutions to support our customers into clinic quickly and effectively l Containment for BSL class 2 microbes
8 About Quay Pharmaceuticals Projects supported by our senior scientific team (>150 years in product development ) comprising of:
9 About Quay Pharmaceuticals Projects supported by our senior scientific team (>150 years in product development ) comprising of: Prof. M. Rubinstein (Chairman)
10 About Quay Pharmaceuticals Projects supported by our senior scientific team (>150 years in product development ) comprising of: Prof. M. Rubinstein (Chairman) Prof. J. Collett
11 About Quay Pharmaceuticals Projects supported by our senior scientific team (>150 years in product development ) comprising of: Prof. M. Rubinstein (Chairman) Prof. J. Collett Prof. L. Gifford
12 Aim Key considerations for oral live biotherapeutic product (LBP) development Critical factors which affect time-line to get to GMP manufacture of drug product Incorporation of quality requirements during development studies
13 Aim Key considerations for oral live biotherapeutic product (LBP) development Critical factors which affect time-line to get to GMP manufacture of drug product Incorporation of quality requirements during development studies Our Focus: to convert drug substance to drug product
14 Quay Considerations Regulatory
15 Quay Considerations Regulatory Manufacturing capability (GMP): MHRA IMP Licence for manufacture (MIA).
16 Development Process for Oral Live Biotherapeutic Products
17 Typical Development Process for Live Biotherapeutics Drug substance typically supplied as freeze dried powder(s) Cell Separation and Stabilisation of Biomass Fermentation Lyophilisation Encapsulation
18 Quay Considerations Drug Substance
19 Quay Considerations Drug Substance Typical Tests Reported on a Certificate of Analysis: LBT (Single Strain) Appearance Identity Confirmation Viable Cell Count Water Content Microbiological Quality
20 Quay Considerations Drug Substance Typical Tests Reported on a Certificate of Analysis: Typical Early Phase Unknowns: LBT (Single Strain) Appearance Identity Confirmation Viable Cell Count Water Content Microbiological Quality Batch to batch consistency VCC & physical characteristic changes. Processing limitations Environmental considerations & process scalability think end in mind Decontamination regimes Validation requirements, & retro plant design considerations.
21 Quay Considerations Formulation Development
22 Quay Considerations Formulation Development ph gradient Stomach Duodenum 5-7 Jejunum 7-9 IIeum 7-8 Microbial biomass cells/ml cells/ml cells/ml 10 8 cells/ml Ileocecal value Colon cells/ml Annu. Rev. Microbiol :411-29
23 Quay Considerations Targeted Oral Delivery
24 Quay Considerations Targeted Delivery Existing polymer systems can be employed: Supplier Range ph Range Evonik Eudragit 5 >7 Shin-Etsu Aqoat 5 7 Colourcon Opadry Enteric 5 7
25 Quay Considerations Targeted Delivery Existing polymer systems can be employed: Supplier Range ph Range Evonik Eudragit 5 >7 Shin-Etsu Aqoat 5 7 Colorcon Opadry Enteric 5 7 Shin-Etsu Aqoat Product Literature
26 Critical Factors Affecting GMP Time-lines
27 Critical Factors Affecting GMP Time-lines
28 Critical Factors Affecting GMP Time-lines - Drug Substance Supply & Quality Chain - GMP audit trail
29 Critical Factors Affecting GMP Time-lines - Drug Substance Supply & Quality Chain - GMP audit trail - Batch to Batch Variation - Be prepared for potency loss on scale up (drug substance and drug product)
30 Critical Factors Affecting GMP Time-lines - Drug Substance Supply & Quality Chain - GMP audit trail - Batch to Batch Variation - Be prepared for potency loss on scale up (drug substance and drug product) - Risk Assess Clinical Design - Build in flexibility
31 Critical Factors Affecting GMP Time-lines - Drug Substance Supply & Quality Chain - GMP audit trail - Batch to Batch Variation - Be prepared for potency loss on scale up (drug substance and drug product) - Risk Assess Clinical Design - Build in flexibility - Ensure Robust Analytics - Identity, potency, critical parameter analysis (including in-vitro release assessment)
32 Critical Factors Affecting GMP Time-lines - Drug Substance Supply & Quality Chain - GMP audit trail - Batch to Batch Variation - Be prepared for potency loss on scale up (drug substance and drug product) - Risk Assess Clinical Design - Build in flexibility - Ensure Robust Analytics - ID, Potency, critical parameter analysis (including in-vitro release assessment) - Drug Product Specification Setting - Get the regulators on board early fast moving landscape
33 Example: Live Biotherapeutic Drug Product Specifications
34 Example: LBP Specifications Test Appearance Identity Content Purity Disintegration Moisture Methodology Visual 16s RNA sequencing Strain specific quantification (CFU/g) Uniformity of dosage units EP Ph. Eur /13 Microbial quality Ph. Eur (media selected in accordance with ph threshold of release controlling polymer) Karl Fischer
35 Summary Prior to initiating drug product development studies Robust analytics (for drug substance) are necessary to support: Fast turnaround of results allowing efficient formulation development time-lines. Product development data essential to set specifications and infer product shelf-life. Formulation design must consider, process restrictions due drug substance sensitivity to achieve targeted delivery. Flexible clinical design to accommodate variable drug substance assay.
36 Thank you QUAYPHARMA.COM
Qualified Persons (IMP) Don Wallace Regional QA Pharmacist 27 th May 2014
Qualified Persons (IMP) Don Wallace Regional QA Pharmacist 27 th May 2014 Introduction EU Clinical Trials Directive 2001 came into existence in the UK in May 2004 (Part 6 Manufacture of Investigational
More informationThe Application of Pharmaceutical cgmp to Live Bacterial Products. James Harris Business Development Manager
The Application of Pharmaceutical cgmp to Live Bacterial Products James Harris Business Development Manager The Objective CMC expectations of a cgmp live bacterial biopharmaceutical project Overview Define
More informationControl Strategy. Implementation of ICH Q8, Q9, Q10
Implementation of ICH Q8, Q9, Q10 Control Strategy International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Introduction Structure of this session
More informationGuidelines for Pharmaceutical Equivalence Requirements
Guidelines for Pharmaceutical Equivalence Requirements Version 1.1 1 September 2010 Page 1 of 9 Guidelines for Pharmaceutical Equivalence Requirements Version 1.1 Drug Sector Saudi Food & Drug Authority
More informationAn Overview of IQ s Position Paper: Early Development GMPs for Small-Molecule Specifications
An Overview of IQ s Position Paper: Early Development GMPs for Small-Molecule Specifications On behalf of Specifications Team Kirby Wong-Moon, Ph.D. Amgen Inc. Best Practices and Application of GMPs for
More informationBalancing the time, cost and risk of drug development. Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL
Balancing the time, cost and risk of drug development Christina Gustafsson, PhD Pharm, Formulation Scientist at Pharmaceutical Development, APL Communicating vessels Risk Time Cost Communicating vessels
More informationQUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS
QUALITY OF PROLONGED RELEASE ORAL SOLID DOSAGE FORMS Guideline Title Quality of Prolonged Release Oral Solid Dosage Forms Legislative basis Directive 75/318/EEC as amended Date of first adoption October
More informationInternational Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW
International Journal of Pharma and Bio Sciences DEVELOPMENT OF ACCELERATED STABILITY PROTOCOL FOR SILDENAFIL TABLETS A EUROPEAN PERSPECTIVE REVIEW SUKHDEV SINGH *1 AND JASBIR SINGH 2 1 Rayat Institute
More informationExcipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance
Excipients Facing Increased Scrutiny How to Use Secondary Reference Standards to Help Maintain Regulatory Compliance by Tom Savage, NSF International Since 2008, when patient deaths were first linked to
More informationRapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products
RapidFACT: Accelerated Formulation Development for Poorly Soluble Drugs and Modified Release Products Kevin Kane, Scientific Director, BCP 7 th Annual Global Drug Delivery & Formulation Summit 28 th August
More informationWhere Quality Meets Flexibility
Where Quality Meets Flexibility is an industry leading 503B Outsourcing Facility providing sterile and non-sterile compounding services to hospitals, surgery centers, clinics, researchers & patients nationwide.
More informationHuman Microbiota: proof of concept to production. Michael van der Horst Process Engineer Technical Operations SynCo Bio Partners B.V.
Human Microbiota: proof of concept to production Michael van der Horst Process Engineer Technical Operations SynCo Bio Partners B.V. SynCo Bio Partners B.V. Who we are and what we do Licensed cgmp CMO
More informationDECISION TREE #1: ESTABLISHING ACCEPTANCE CRITERION FOR A SPECIFIED IMPURITY IN A NEW DRUG SUBSTANCE
DECISION TREE #1: ESTABLISHING ACCEPTANCE CRITERION FOR A SPECIFIED IMPURITY IN A NEW DRUG SUBSTANCE Determine impurity level in relevant batches 1 Determine mean + upper confidence limit for the impurity
More informationDRAFT OECD GLP ADVISORY DOCUMENT NO. 19 ON THE MANAGEMENT, CHARACTERISATION AND USE OF TEST ITEMS PREAMBLE
DRAFT OECD GLP ADVISORY DOCUMENT NO. 19 ON THE MANAGEMENT, CHARACTERISATION AND USE OF TEST ITEMS PREAMBLE 1. This guidance provides clarity for test facilities on the expectations of national Good Laboratory
More informationQuality aspects Overview. QP declaration
Quality aspects Overview QP declaration Standards for the quality part of the dossier with focus on: - Materials from animals, nosodes - Proof of microbiological quality, pesticides, heavy metals, organic
More information3M Drug Delivery Systems. April 26, 2011
3M MDI Manufacturing April 26, 2011 3M Drug Delivery Systems Drug Delivery Systems Overview 3M Drug Delivery Systems is a division of 3M that is dedicated to the development and manufacturing of inhalation
More informationAuditing Your Laboratory for Compliance with the FDA Dietary Supplement GMP s
Tech Tip 0020 With the advent of the cgmp s, the majority of companies are increasing the frequency of their outsourced analytical testing. But the GMPs are just that, Good Manufacturing Practices, and
More informationAdaptDose, an innovative platform that reduces product development time and costs by 30% or more
WHITE PAPER January 2017 AdaptDose, an innovative platform that reduces product development time and costs by 30% or more Frontida BioPharm, Inc. Ron Connolly 01.01.2017 CONTENTS ABSTRACT INTRODUCTION
More informationGMP Inspection Deficiencies Review of Deficiencies Observed in 2013.
GMP Inspection Deficiencies 2013 Review of Deficiencies Observed in 2013. Executive Summary The most frequently encountered defect categories raised over the previous five years have remained relatively
More informationWhy Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services
Why Do I Test, What Do I Test & When Do I Test It? Ross Caputo, PhD Chief Technical Officer Eagle Analytical Services Disclosures I, Ross Caputo, declare no conflicts of interest, real or apparent, and
More informationCRITICAL ASPECT ANALYTICAL TEST REVIEW
CRITICAL ASPECT ANALYTICAL TEST REVIEW Jakarta 14 December 2017 Speaker: HERU PURNOMO, ST QC WORK FLOW Start Sample Received (In-Process & Finished Good) Testing Review Lab Result Yes No Non Conformance
More informationLEGAL REQUIREMENTS FOR STABILITY
BY DR. A.V.PRABHU LEGAL REQUIREMENTS FOR STABILITY 21 CFR 211.166- STABILITY TESTING GMP To assess stability characteristics to determine storage conditions and expiration dates. Written stability program
More informationTEST PROCEDURES AND ACCEPTANCE CRITERIA FOR NEW VETERINARY DRUG SUBSTANCES AND NEW MEDICINAL PRODUCTS: CHEMICAL SUBSTANCES
VICH GL39 (QUALITY) November 2005 For implementation at Step 7 TEST PROCEDURES AND ACCEPTANCE CRITERIA FOR NEW VETERINARY DRUG SUBSTANCES AND NEW MEDICINAL PRODUCTS: CHEMICAL SUBSTANCES Recommended for
More informationINTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH HARMONISED TRIPARTITE GUIDELINE SPECIFICATIONS: TEST PROCEDURES AND ACCEPTANCE
More informationContents. Contents (13) 1 Production (23)
1 Production (23) 1.A Sanitation (27) 1.A.1 Organisational prerequisites (27) 1.A.2 Sources of contamination (28) 1.A.3 Responsibilities and implementation (29) 1.B Personnel hygiene (31) 1.B.1 Clothing
More informationDetection and Quantitation of Residual Host Cell DNA
Detection and Quantitation of Residual Host Cell DNA White Paper Author: Phil Kuhlman, Biopharmaceutical Technical Specialist 1 Abstract All biological drug products are required to be characterised for
More informationInternationally harmonised requirements for batch certification
1 June 2011 EMA/INS/MRA/387218/2011 Rev 5 Compliance and Inspection Internationally harmonised requirements for batch certification in the context of Mutual Recognition Agreements, Agreements on Conformity
More informationPHARMACEUTICAL TESTING
WHITEHOUSE, NJ PHARMACEUTICAL TESTING Pharmaceutical Expertise for GMP & CMC Testing Our Pharmaceutical Expertise With more than 20 years of experience in a variety of industries, our Whitehouse, New Jersey
More informationPhase Appropriate GMPs for IMPs. Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017
Phase Appropriate GMPs for IMPs Presented by: Karen S. Ginsbury For: IFF, October 31, Nov 02, 2017 1 Lets start with References https://mhrainspectorate.blog.gov.uk/2016/0 5/20/manufacture-of-investigationalmedicinal-products-frequently-askedquestions/
More informationANNEX III ASEAN GUIDELINES ON LIMITS OF CONTAMINANTS FOR HEALTH SUPPLEMENTS
Association of South East Asian Nations (ASEAN) ANNEX III ASEAN GUIDELINES ON LIMITS OF CONTAMINANTS FOR HEALTH SUPPLEMENTS Disclaimer: This document is provided for information purpose only and subject
More informationQualified Persons in the Pharmaceutical Industry Study Guide
Qualified Persons in the Pharmaceutical Industry Study Guide Guide to the knowledge and practical experience required by Qualified Persons relating to pharmaceutical manufacturing in the UK February 2013
More informationStability of Biological Products
Stability of Biological Products Dr Jurgen Lindner Principal, BioPharma Consulting & Executive Secretary, APIMAA Biological Products Functional Proteins or Polypeptides (mab s, enzymes & inhibitors, growth
More informationEarly Development Best Practices for Stability- Regulatory Perspective
Early Development Best Practices for Stability- Regulatory Perspective IQ Workshop, Feb. 4-5, 2014, Washington, D.C. Ramesh Sood, Ph.D. Division Director (Acting) Office of New Drug Quality Assessment
More informationEUROPEAN INDUSTRIAL PHARMACISTS GROUP. Guidance on CPD for QUALIFIED PERSONS
EUROPEAN INDUSTRIAL PHARMACISTS GROUP Guidance on CPD for QUALIFIED PERSONS EIPG Guidance on CPD for QP Continuing Professional Development for Qualified Persons, Technical Directors and other Responsible
More informationUSP s Perspective on Drug Product Performance Test
USP s Perspective on Drug Product Performance Test Course Overview 1. The concept of in vitro dissolution Definition and application 2. Compendial dissolution/ drug release testing 3. Method development
More informationTranslational Pharmaceutics : a unique platform to accelerate early oncology development
Translational Pharmaceutics : a unique platform to accelerate early oncology development Lisa Clarke-Lens, Associate Director, Oncology Services Quotient Clinical Clinical Operations in Oncology Trials
More informationBiologics. Biologics. The Centre for Process Innovation. From innovation to commercialisation
Biologics Biologics The Centre for Process Innovation From innovation to commercialisation The Centre for Process Innovation From innovation to commercialisation The High Value Manufacturing Catapult is
More informationBioavailability and Bioequivalence Studies
Bioavailability and Bioequivalence Studies Standard Approach Part I: Design and Conduct H. Rettig, Ph.D. LLC www.ivivc.com Note for Guidance on the Investigation of Bioavailability and Bioequivalence CPMP/EWP/QWP/1401/98
More informationWe make drugs smarter
We make drugs smarter Brookwood Pharmaceutical Services WE MAKE DRUGS SMARTER Using our 40 years of experience, our state of the art facilities and our IP protected technologies, we leverage existing capabilities
More informationCorporate Presentation
Corporate Presentation 1 Development Tool Medicine Stabicon Life Sciences Wellness Health Supplement Ethos Vision: Lead the way to a healthier world by partnering with Pharmaceutical Community across the
More informationManagement Team. Over 35 years experience in the pharmaceuticals industry
2017 1 Overview Located in Bangalore, a Dedicated cgmp and cglp Compliance Laboratory Established in September 2010 Approved Contract research Organization by India FDA Approved by Health Canada since
More informationPublic Assessment Report. Scientific discussion. Progesteron GLF 100 mg and 200 mg soft capsules. (progesterone) NL/H/3415/ /DC
Public Assessment Report Scientific discussion Progesteron GLF 100 mg and 200 mg soft capsules (progesterone) 001-002/DC Date: 6 June 2017 This module reflects the scientific discussion for the approval
More informationBiotechpharma company profile. Romanas Ramanauskas Business development manager
Biotechpharma company profile Romanas Ramanauskas Business manager October, 2012 1 Contents History Company overview Services and capabilities Expression system and process Technology scale-up and GMP
More informationEvonik Birmingham Laboratories
Evonik Birmingham Laboratories An integrated CDMO for advanced parenterals with a portfolio of delivery technologies, formulation development services and GMP manufacturing Evonik Birmingham Laboratories
More informationPreparing the CMC section of IMPD for biological/biotechnology derived substances
Preparing the CMC section of IMPD for biological/biotechnology derived substances Your Logo Dr. Una Moore Health Products Regulatory Authority, Ireland Presented by Una Moore on 16 th April 2014. Health
More informationHow to Identify Critical Quality Attributes and Critical Process Parameters
How to Identify Critical Quality Attributes and Critical Process Parameters Jennifer Maguire, Ph.D. Daniel Peng, Ph.D. Office of Process and Facility (OPF) OPQ/CDER/FDA FDA/PQRI 2 nd Conference North Bethesda,
More informationICH Q9 An Industry Perspective: Ensuring Quality to Patients in a Risk-Based Regulatory Environment
ICH Q9 An Industry Perspective: Ensuring Quality to Patients in a Risk-Based Regulatory Environment Thomas Schultz, Ph.D. Director, Regulatory Sciences Johnson & Johnson September 12, 2007 Presentation
More informationQ8 Pharmaceutical Development
Q8 Pharmaceutical Development For questions regarding this draft document contact (CDER) Ajaz Hussain at 301-594-2847 or (CBER) Christopher Joneckis at 301-435-5681. This draft guidance, when finalized,
More informationExtending Beyond Use Dating for Compounded Preparations Webinar Q&A
Stability Studies 1. If potency over time studies are not acceptable to extend BUD, then why is it offered? Potency point-in-time studies only indicate the potency of a compounded preparation at that specific
More informationPharmaceutical quality requirements
Pharmaceutical quality requirements through development to commercial medicinal product December 4, 2014 Karin Walhagen Biomedicine the Profession Biomedicine Master Program at Lund University Patient
More informationABF Pharmaceutical Services GmbH
ABF Pharmaceutical Services GmbH Facts and Figures GBA is a European laboratory group with an annual turnover of +40 M. Founded in 1989, Hamburg Our business covers Pharma, Environmental, Foodstuff, Consumer
More informationExtending Beyond Use Dating for Compounded Preparations Webinar Q&A
Stability Studies 1. If potency over time studies are not acceptable to extend BUD, then why is it offered? Potency point-in-time studies only indicate the potency of a compounded preparation at that specific
More informationQuality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review
Quality Issues for Clinical Trial Materials: The Chemistry, Manufacturing and Controls (CMC) Review Presented by Erika E. Englund, Ph.D. Slides courtesy of Dorota Matecka, Ph.D. Office of Pharmaceutical
More informationDMTC Technology Readiness Levels Guideline
Technology Readiness Levels Technology Readiness Levels (TRLs) are used as standardised numerical indicators of the level of maturity of a technology. The standard TRL definitions are given in Table 1.
More informationPublic Assessment Report. Scientific discussion
Public Assessment Report Scientific discussion Moxalole Powder for oral solution (Macrogol 3350, sodium chloride, sodium hydrogen carbonate, potassium chloride) DK/H/1199/001/DC This module reflects the
More informationAccelerating development of enabled formulations for poorly soluble drugs
Accelerating development of enabled formulations for poorly soluble drugs John McDermott, Executive Director, Drug Product Optimisation Efficacy issues due to inadequate gastrointestinal (GI) absorption
More informationQuality of raw materials and manufacturing of advanced therapies. Fouad Atouf, Ph.D. Head, Global Biologics July 12, 2018
Quality of raw materials and manufacturing of advanced therapies Fouad Atouf, Ph.D. Head, Global Biologics July 12, 2018 Evolution of the compendia 1820: a single recipe book 2018: Procedures and acceptance
More informationJournal of Atoms and Molecules
Review article Journal of Atoms and Molecules An International Online Journal ISSN 2277 1247 CLEANING VALIDATION IN PHARMACEUTICAL INDUSTRIES Abhishek Raj Senior R&D Officer, Quest Pharmaceuticals Pvt.
More informationQuality Assurance of RUTF and similar products. Future areas of focus!
1 Quality Assurance of RUTF and similar products. Future areas of focus! Peter S. Jakobsen 12 September 2013 Quality Assurance Centre SUPPLY DIVISION pjakobsen@unicef.org 2 RUTF Ready to Use Therapeutic
More informationHow to ensure the Stability of Products in Clinical Trials an Industry Perspective. Volker Schnaible
How to ensure the Stability of Products in Clinical Trials an Industry Perspective Volker Schnaible Outline Why do we need stable development products? How to ensure stability How to use stability data
More informationMicrobiological Consideration for Non-Sterile Pharmaceutical
May 1-3, 2012 Javits Center New York, NY Microbiological Consideration for Non-Sterile Pharmaceutical Dr. Leonard W. Mestrandrea Principal Consultant MESTRANDREA CONSULTING LLC Title Date Microbial Control
More informationImplementation of PAT for Real Time Release Testing. Mark Smith Process Analytical Sciences Group Pfizer, Cork
Implementation of PAT for Real Time Release Testing Mark Smith Process Analytical Sciences Group Pfizer, Cork PAT at Pfizer A key enabler for transformational strategies and new quality paradigms 9 Delivering
More informationA Comprehensive Approach to Find and Remediate Data Integrity Problems
A Comprehensive Approach to Find and Remediate Data Integrity Problems June 14, 2017 Copyright 2017 QuintilesIMS. All rights reserved. What is data integrity? Whom does it apply to? Definitions matter
More informationICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon
ICH Q3D Guideline Impact on the Users: Perspective of a Finished Product Manufacturer John Glennon 9 November 2016 Disclaimer The views and opinions expressed in this presentation are those of the author
More informationMHRA Telephone Ref: 1099/Flutcore Ms Nathalie Gilmore Direct line: (0)
Ms Martina Tomcalova ELC Group s.r.o Karolinska 650/1 186 00 Prague 8 Czech Republic Monday 11 th January 2016 MHRA 151 Buckingham Palace Road Victoria London SW1W 9SZ United Kingdom Telephone +44 (0)
More informationBasis for setting acceptance criteria
Basis for setting acceptance criteria Mats Welin, Senior expert Medical Products Agency, BWP Disclaimer: The views presented in the presentation are my own and not necessarily the ones of BWP Fundamentals
More informationWorking document QAS/ June 2011 RESTRICTED DRAFT FOR COMMENT
June 2011 RESTRICTED DRAFT PROPOSAL FOR Revision of General method in the 4th Edition of The International Pharmacopoeia 3.3 MICROBIAL PURITY OF PHARMACEUTICAL PREPARATIONS (June 2011) DRAFT FOR COMMENT
More informationPartnering for Impact Human Health Therapeutics
Partnering for Impact Human Health Therapeutics Bernard Massie General Manager Human Health Therapeutics Partnering for Impact in Biologics and Vaccines NRC s Human Health Therapeutics (HHT) portfolio
More informationIndustry Perspective on Manufacturing in Early Development
Industry Perspective on Manufacturing in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Eric Schmitt AbbVie IQ Drug Product Manufacturing Working Group August 2012 issue of Pharmaceutical
More informationEstablished Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry
Established Conditions: Reportable CMC Changes for Approved Drug and Biologic Products Guidance for Industry DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments
More informationMicroSEQ Rapid Microbial Identification System
MicroSEQ Rapid Microbial Identification System Giving you complete control over microbial identification using the gold-standard genotypic method The MicroSEQ ID microbial identification system, based
More informationBest Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C.
Best Practices and Application of GMPs for Small Molecule Drugs in Early Development IQ Workshop, Feb 4-5, 2014, Washington, D.C. Specifications Breakout Session 2 Pete Yehl and Mike Coutant, moderators
More informationStability Testing of Drug Products
Stability Testing of Drug Products Scientific Criteries, guidelines and officiel state requirements in Europe, Japan and USA Edited by Dr. Wolfgang Grimm, Dr. Karl Thomae GmbH, D-Biberach International
More informationInspection of Quality Control Laboratories
Inspection of Quality Control Laboratories PQP Manufacturer's Meeting April 4-5 th 2011, Geneva, Switzerland Stephanie Croft, M.Sc. Technical Officer (Inspector), WHO Prequalification of Medicines Programme
More informationQuality Assurance in Pharmaceutical and Biotech Industries as Per Regulatory Guidelines
Human Journals Review Article January 2017 Vol.:8, Issue:2 All rights are reserved by Chagi Venkatesh et al. Quality Assurance in Pharmaceutical Biotech Industries as Per Regulatory Guidelines Keywords:
More informationQuality by Design (QbD)
Evaluating the Critical Quality attributes & Critical Process Parameters-A Case Study-Tablets GMP International Workshop February 20/21, 2008 Mumbai, India Mukund Yelvigi Director, Therapeutic Area Management,
More informationManufacturing Considerations for Liposomal Drug Products. Nanotechnology Workshop January 2014
Manufacturing Considerations for Liposomal Drug Products Nanotechnology Workshop January 2014 Applications of Nano-Scale Drug Delivery Systems Wide range of carrier types Liposomes Solid core nanoparticles
More informationPrimary / secondary standards in pharmaceutical QC. Dr. Christian Zeine LGC Standards GmbH. Webinar Series 2013 July 2013
Primary / secondary standards in pharmaceutical QC Dr. Christian Zeine LGC Standards GmbH Webinar Series 2013 July 2013 Quick guide to the webinar tools Slide 2 Topics of today s talk Close look on: Main
More informationGuideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials
EUROPEAN COMMISSION HEALTH AND CONSUMERS DIRECTORATE- GENERAL Health systems and products Medicinal products quality, safety and efficacy 18 February 2010 EMA/CHMP/BWP/534898/2008 Committee for Medicinal
More informationCQAs for C> Products to Enable Comparability Assessment. Ben Thompson Snr Director, Biopharmaceutical CMC RA GlaxoSmithKline
CQAs for C> Products to Enable Comparability Assessment Ben Thompson Snr Director, Biopharmaceutical CMC RA GlaxoSmithKline Overview Demonstrate the value of defining CQAs early in product development
More informationFROM CLINICAL TO COMMERCIAL CUSTOM CAN. An overview of our Development and Manufacturing capabilities
FROM CLINICAL TO COMMERCIAL CUSTOM CAN An overview of our Development and Manufacturing capabilities THE CUSTOM DIFFERENCE Established in 1979, Custom Pharma Services has grown to become the go-to resource
More informationChromeleon CDS delivers efficiency gains and compliance and data integrity improvements to UK CRO/CMO
CASE STUDY Sterling Pharma Solutions Chromeleon CDS delivers efficiency gains and compliance and data integrity improvements to UK CRO/CMO Brian Alliston is currently a Data Integrity Expert and CDS Specialist
More informationPharmaceutical product technical requirements and the Interagency pharmaceutical product questionnaire
Pharmaceutical product technical requirements and the Interagency pharmaceutical product questionnaire Atieno Ojoo Technical specialist, Pharmaceuticals UNICEF Supply Division 20 th October 2008, UNICEF
More informationRecent experience in scientific advice and marketing authorisations
Recent experience in scientific advice and marketing authorisations Presented by Brigitte Brake on 16 April 2015 BfArM & BWP, Germany An agency of the European Union Introduction Short introduction to
More informationReal-Time Prediction of Polymer-Coated Multiparticulate Dissolution using Process Analytical Technology
Real-Time Prediction of Polymer-Coated Multiparticulate Dissolution using Process Analytical Technology Authors: Piyush Patel A, Edward Godek B, Chris O Callaghan C, Dr. Ian Jones D A Colorcon, PA, USA
More informationDIFFERING CMC REQUIREMENTS: US AND EU
WHITEPAPER DIFFERING CMC REQUIREMENTS: US AND EU Torsten Schnetgoeke M.Sc. Senior Manager, Regulatory Affairs torsten.schnetgoeke@pharmalex.com Torsten joined PharmaLex in 2015 as a Senior Manager in Regulatory
More informationPharmaceutical Manufacturing Technology Centre
Pharmaceutical Manufacturing Technology Centre Research themes for Initial Research Programme Call for Proposals The Centre will focus on advanced pharmaceutical manufacturing technologies with an initial
More informationMacromolecules in E-Workbook
Macromolecules in E-Workbook Ian Peirson March 2018 So what do we mean by macromolecules? Small molecules MW
More informationGMPs for Method Validation in Early Development: An Industry Perspective (Part II)
GMPs for Method Validation in Early Development: An Industry Perspective (Part II) Pharmaceutical Technology Volume 36, Issue 7, pp. 76-84 Henrik T. Rasmussen, Vertex Pharmaceuticals, Inc. Donald Chambers,
More informationMicrobiology for Oral and Topical Products - The basics Scott Colbourne Business Manager NSW ALS Food & Pharmaceutical
Microbiology for Oral and Topical Products - The basics Scott Colbourne Business Manager NSW ALS Food & Pharmaceutical RIGHT S O L U T I O N S RIGHT PARTNER Contents TGO 77 - Introduction Tests Performed
More informationGUIDANCE DOCUMENT Use of a Foreign-sourced Reference Product as a Canadian Reference Product
GUIDANCE DOCUMENT Use of a Foreign-sourced Reference Product as a Canadian Reference Product Published by authority of the Minister of Health Date Adopted 2017/11/24 Effective Date 2017/11/24 Health Products
More informationOECD SERIES ON PRINCIPLES OF GOOD LABORATORY PRACTICE AND COMPLIANCE MONITORING Number 19
Organisation for Economic Co-operation and Development ENV/JM/MONO(2018)6 English - Or. English 19 April 2018 ENVIRONMENT DIRECTORATE JOINT MEETING OF THE CHEMICALS COMMITTEE AND THE WORKING PARTY ON CHEMICALS,
More informationAssembly Biosciences Jefferies 2015 Microbiome Summit. December 16, 2015
Assembly Biosciences Jefferies 2015 Microbiome Summit December 16, 2015 Forward-Looking Statements This presentation contains forward-looking statements regarding future events. Forward-looking statements
More informationCurrent Regulatory Thinking The Draft Reflection Paper On Intravenous Liposomal Product Quality Issues
Current Regulatory Thinking The Draft Reflection Paper On Intravenous Liposomal Product Quality Issues Dr. René Thürmer BfArM - and dmedical ldevices AGAH Workshop on Liposomal Formulations Bonn / 21.
More informationRegulatory Expectations for Method Transfers: Health Canada's Perspective CMC Strategy Forum Methods on the move January 23, 2017
Regulatory Expectations for Method Transfers: Health Canada's Perspective CMC Strategy Forum Methods on the move January 23, 2017 Hugo Hamel, Senior Biologist/Evaluator, BGTD Overview of the Post-NOC Changes
More informationLeveraging Health Canada s Regulatory Framework to Accommodate Accelerated Product Development for Biologic Drugs
Leveraging Health Canada s Regulatory Framework to Accommodate Accelerated Product Development for Biologic Drugs Nancy Green, Ph.D. Chief, Hormones and Enzymes Division Biologics and Genetic Therapies
More informationDraft regional guidelines on stability testing of active substances and pharmaceutical products
Regional Committee for the EM/RC53/12 Eastern Mediterranean August 2006 Fifty-third Session Original: Arabic Agenda item 17 Draft regional guidelines on stability testing of active substances and pharmaceutical
More informationSetting Specifications for Biotech Products
Setting Specifications for Biotech Products Session 1: What to Control? Presentation by an EU Regulator Nanna Aaby Kruse, Senior Biological Assessor, member of BWP and BMWP WHAT TO CONTROL? Control of
More information11 th INTERNATIONAL SYMPOSIUM ON PHARMACEUTICAL REFERENCE STANDARDS. Siriphorn Laomanacharoen 21 December 2012
11 th INTERNATIONAL SYMPOSIUM ON PHARMACEUTICAL REFERENCE STANDARDS Siriphorn Laomanacharoen 21 December 2012 11 th INTERNATIONAL SYMPOSIUM ON PHARMACEUTICAL REFERENCE STANDARDS Organised by European Directorate
More informationGuide. recombinant DNA proteins. for the elaboration of monographs on synthetic peptides and. European Pharmacopoeia
Guide for the elaboration of monographs on synthetic peptides and recombinant DNA proteins European Pharmacopoeia European Directorate for the Quality of Medicines & HealthCare Edition Council of Europe,
More information